FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108051> ?p ?o ?g. }

• W4310108051 endingPage "2364" @default.
• W4310108051 startingPage "2362" @default.
• W4310108051 abstract "Background Major limitations to CD19-targeted chimeric antigen receptor T (CART19) cell therapy include suboptimal antitumor activity and development of life-threatening toxicities such as cytokine release syndrome (CRS) and neurotoxicity. CART-associated toxicities are directly related to CART activation and proliferation in vivo. Emerging data suggest that CART over-activation contributes to therapeutic failure. Objective We hypothesized that modulation of CART activation reduces the risk of CRS while enhancing CART efficacy. Specifically, we hypothesized that using the clinically-approved CD19 monoclonal antibody tafasitamab prior to CART19 therapy can reduce tumor pyroptosis (inflammatory lytic programmed cell death), modulate CART activation, and enhance CART therapeutic index. Results First, we tested the optimal sequencing of tafasitamab and CART19 in preclinical models. We used a 4-1BB costimulated CART19 construct, similar to FDA-approved tisagenlecleucel. Our data indicate that sequential use of tafasitamab followed by CART19 ameliorated overactivation, prevented apoptosis, and improved antitumor activity of CART19 in xenograft models (Sakemura et al, ASH 2021). Given the reduction of CART19 apoptosis after treatment with tafasitamab, we aimed to determine the effect of tafasitamab on tumor pyroptosis. Here, we measured the level of high mobility group box-1 (HMGB-1) in CD19+ tumor cells after co-culture with CART19 and tafasitamab. CD19 modulation with tafasitamab resulted in a significant reduction of HMGB-1, which indicates reduced tumor pyroptosis. Given these in vitro results, we aimed to study how CD19 occupancy with tafasitamab prior to CART19 infusion impacts tumor pyroptosis in vivo. We utilized a mouse model that mimics CART toxicities. Immunocompromised NSG mice were inoculated via tail vein with 3-5x106 leukemic cells derived from patients with relapsed/refractory acute lymphoblastic leukemia (Sterner et al. Blood 2019, Sakemura et al. Cancer Immunol Res. 2021). Three weeks later, tumor burden was assessed by peripheral blood sampling. Leukemic cells were defined as murine CD45- and human CD45+CD19+CD20+ via flow cytometry, and volumetric absolute number was calculated. Mice were then randomized according to tumor burden to receive IgG control antibody one week before CART19 infusion [Group 1 (G1)], 5 mg/kg/day of tafasitamab one week before CART19 infusion (G2) or no treatment (G3). CRS was determined by weight loss, development of motor weakness, poor body posture, and elevated serum cytokine levels (e.g., IL-6, MCP-1, sCD40L, and GM-CSF). Prior to CART19 infusion, absolute number of CD19 molecules on tumor cells was quantified with antigen-binding capacity beads. G2 showed significant reduction of unbound/detectable CD19 molecules on the leukemic cell surface compared to G1 and G3. On day 0, 3x106 luciferase+CART19 were injected into G1 and G2 via tail vein. Mice were monitored with weekly bioluminescent imaging to track and quantify CART19 expansion and daily weighing and physical assessment to detect toxicity. G1 demonstrated significant weight reduction, motor weakness, and rapid CART19 expansion compared to G2. G1 reached an endpoint within 5 days of CART19 administration due to CRS, while G2 had delayed weight reduction and CART19 expansion. However, all mice from G2 remained healthy and did not display signs of CRS, including motor weakness and hunched posture. On day 5, CRS-related serum cytokines/chemokines were significantly elevated in G1 compared to G2. Overall survival was significantly longer in G2 (Fig 1A). Spleens were harvested, weighed, and assessed with flow cytometry. Spleens from G1 and G3 were significantly enlarged and were mainly composed of CD20+ leukemic cells compared to G2 spleens, which were smaller and infiltrated with CD3+ CART cells but not leukemic cells. Satellite mice were euthanized on day 1 and spleens were harvested. Western blot analysis revealed that mice from G1 showed significantly lower expression of apoptosis-inducing protein Gasdermin E (GSDME) and higher expression of cleaved GSDME on leukemic cells compared with G2, indicating reduced tumor pyroptosis in G2 (Fig 1B). Conclusions In summary, CD19 binding with tafasitamab improved leukemic disease control and decreased the incidence and severity of CRS after CART19 administration in vivo, in part through the reduction of tumor pyroptosis. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310108051 created "2022-11-30" @default.
• W4310108051 creator A5000383195 @default.
• W4310108051 creator A5002515721 @default.
• W4310108051 creator A5003521951 @default.
• W4310108051 creator A5008200184 @default.
• W4310108051 creator A5009747339 @default.
• W4310108051 creator A5012147403 @default.
• W4310108051 creator A5014970964 @default.
• W4310108051 creator A5015801018 @default.
• W4310108051 creator A5021651622 @default.
• W4310108051 creator A5024397284 @default.
• W4310108051 creator A5030347346 @default.
• W4310108051 creator A5031777309 @default.
• W4310108051 creator A5034569036 @default.
• W4310108051 creator A5035529864 @default.
• W4310108051 creator A5044081852 @default.
• W4310108051 creator A5048214136 @default.
• W4310108051 creator A5051172989 @default.
• W4310108051 creator A5054196868 @default.
• W4310108051 creator A5061713890 @default.
• W4310108051 creator A5067492340 @default.
• W4310108051 creator A5069575998 @default.
• W4310108051 creator A5072015517 @default.
• W4310108051 creator A5073806084 @default.
• W4310108051 creator A5086659894 @default.
• W4310108051 creator A5088363243 @default.
• W4310108051 creator A5090781979 @default.
• W4310108051 date "2022-11-15" @default.
• W4310108051 modified "2023-10-16" @default.
• W4310108051 title "CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy" @default.
• W4310108051 doi "https://doi.org/10.1182/blood-2022-158273" @default.
• W4310108051 hasPublicationYear "2022" @default.
• W4310108051 type Work @default.
• W4310108051 citedByCount "0" @default.
• W4310108051 crossrefType "journal-article" @default.
• W4310108051 hasAuthorship W4310108051A5000383195 @default.
• W4310108051 hasAuthorship W4310108051A5002515721 @default.
• W4310108051 hasAuthorship W4310108051A5003521951 @default.
• W4310108051 hasAuthorship W4310108051A5008200184 @default.
• W4310108051 hasAuthorship W4310108051A5009747339 @default.
• W4310108051 hasAuthorship W4310108051A5012147403 @default.
• W4310108051 hasAuthorship W4310108051A5014970964 @default.
• W4310108051 hasAuthorship W4310108051A5015801018 @default.
• W4310108051 hasAuthorship W4310108051A5021651622 @default.
• W4310108051 hasAuthorship W4310108051A5024397284 @default.
• W4310108051 hasAuthorship W4310108051A5030347346 @default.
• W4310108051 hasAuthorship W4310108051A5031777309 @default.
• W4310108051 hasAuthorship W4310108051A5034569036 @default.
• W4310108051 hasAuthorship W4310108051A5035529864 @default.
• W4310108051 hasAuthorship W4310108051A5044081852 @default.
• W4310108051 hasAuthorship W4310108051A5048214136 @default.
• W4310108051 hasAuthorship W4310108051A5051172989 @default.
• W4310108051 hasAuthorship W4310108051A5054196868 @default.
• W4310108051 hasAuthorship W4310108051A5061713890 @default.
• W4310108051 hasAuthorship W4310108051A5067492340 @default.
• W4310108051 hasAuthorship W4310108051A5069575998 @default.
• W4310108051 hasAuthorship W4310108051A5072015517 @default.
• W4310108051 hasAuthorship W4310108051A5073806084 @default.
• W4310108051 hasAuthorship W4310108051A5086659894 @default.
• W4310108051 hasAuthorship W4310108051A5088363243 @default.
• W4310108051 hasAuthorship W4310108051A5090781979 @default.
• W4310108051 hasBestOaLocation W43101080511 @default.
• W4310108051 hasConcept C121608353 @default.
• W4310108051 hasConcept C126322002 @default.
• W4310108051 hasConcept C147483822 @default.
• W4310108051 hasConcept C159654299 @default.
• W4310108051 hasConcept C203014093 @default.
• W4310108051 hasConcept C2777701055 @default.
• W4310108051 hasConcept C2778957590 @default.
• W4310108051 hasConcept C3875195 @default.
• W4310108051 hasConcept C502942594 @default.
• W4310108051 hasConcept C542903549 @default.
• W4310108051 hasConcept C71924100 @default.
• W4310108051 hasConceptScore W4310108051C121608353 @default.
• W4310108051 hasConceptScore W4310108051C126322002 @default.
• W4310108051 hasConceptScore W4310108051C147483822 @default.
• W4310108051 hasConceptScore W4310108051C159654299 @default.
• W4310108051 hasConceptScore W4310108051C203014093 @default.
• W4310108051 hasConceptScore W4310108051C2777701055 @default.
• W4310108051 hasConceptScore W4310108051C2778957590 @default.
• W4310108051 hasConceptScore W4310108051C3875195 @default.
• W4310108051 hasConceptScore W4310108051C502942594 @default.
• W4310108051 hasConceptScore W4310108051C542903549 @default.
• W4310108051 hasConceptScore W4310108051C71924100 @default.
• W4310108051 hasIssue "Supplement 1" @default.
• W4310108051 hasLocation W43101080511 @default.
• W4310108051 hasOpenAccess W4310108051 @default.
• W4310108051 hasPrimaryLocation W43101080511 @default.
• W4310108051 hasRelatedWork W1602847563 @default.
• W4310108051 hasRelatedWork W1943797027 @default.
• W4310108051 hasRelatedWork W1991697133 @default.
• W4310108051 hasRelatedWork W1997716688 @default.
• W4310108051 hasRelatedWork W1998831848 @default.
• W4310108051 hasRelatedWork W1999800479 @default.
• W4310108051 hasRelatedWork W2029145496 @default.
• W4310108051 hasRelatedWork W2038126255 @default.
• W4310108051 hasRelatedWork W2064089409 @default.

• next